Meriva® 	Meriva® 	 NNP	B-NP
,  	,  	 ,	O
a  	a  	 DT	O
lecithinized  	lecithinized  	 JJ	B-NP
curcumin  	curcumin  	 JJ	I-NP
delivery  	delivery  	 NN	I-NP
system 	system 	 NN	I-NP
,  	,  	 ,	O
in  	in  	 IN	O
diabetic  	diabetic  	 JJ	B-NP
microangiopathy  	microangiopathy  	 NN	I-NP
and  	and  	 CC	O
retinopathy  	retinopathy  	 NN	B-NP
In  	In  	 IN	O
the  	the  	 DT	O
present  	present  	 JJ	O
study 	study 	 NN	O
,  	,  	 ,	O
the  	the  	 DT	O
improvement  	improvement  	 NN	O
of  	of  	 IN	O
diabetic  	diabetic  	 JJ	B-NP
microangiopathy  	microangiopathy  	 NN	I-NP
and  	and  	 CC	O
retinopathy  	retinopathy  	 NNS	B-NP
was  	was  	 VBD	O
evaluated  	evaluated  	 VBN	O
in  	in  	 IN	O
38  	38  	 CD	O
diabetic  	diabetic  	 CD	O
patients  	patients  	 NNS	O
treated  	treated  	 VBN	O
with  	with  	 IN	O
a  	a  	 DT	O
novel  	novel  	 NN	O
curcumin  	curcumin  	 VBZ	O
phospholipids  	phospholipids  	 JJ	B-NP
delivery  	delivery  	 NN	I-NP
form  	form  	 NN	I-NP
( 	( 	 -LRB-	O
Meriva® 	Meriva® 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
Diabetes  	Diabetes  	 NNP	O
was  	was  	 VBD	O
diagnosed  	diagnosed  	 VBN	O
at  	at  	 IN	O
least  	least  	 JJS	O
5  	5  	 CD	O
years  	years  	 NNS	O
before  	before  	 IN	O
inclusion  	inclusion  	 NN	O
and  	and  	 CC	O
all  	all  	 DT	O
patients  	patients  	 NNS	O
had  	had  	 VBD	O
signs  	signs  	 NNS	O
of  	of  	 IN	O
retinal  	retinal  	 JJ	B-NP
oedema  	oedema  	 NN	I-NP
and  	and  	 CC	O
of  	of  	 IN	O
peripheral  	peripheral  	 JJ	B-NP
microangiopathy 	microangiopathy 	 NN	I-NP
.  	.  	 .	O
Meriva®  	Meriva®  	 NNP	B-NP
was  	was  	 VBD	O
administered  	administered  	 VBN	O
at  	at  	 IN	O
the  	the  	 DT	O
dosage  	dosage  	 NN	O
of  	of  	 IN	O
2  	2  	 CD	O
tablets 	tablets 	 CD	B-NP
/ 	/ 	 CD	I-NP
day  	day  	 NN	I-NP
( 	( 	 -LRB-	O
each  	each  	 DT	O
tablet  	tablet  	 NN	O
containing  	containing  	 VBG	O
500  	500  	 CD	O
mg  	mg  	 CD	B-NP
Meriva®  	Meriva®  	 CD	I-NP
corresponding  	corresponding  	 JJ	O
to  	to  	 TO	O
100  	100  	 CD	O
mg  	mg  	 CD	B-NP
curcumin 	curcumin 	 CD	I-NP
)  	)  	 -RRB-	O
for  	for  	 IN	O
a  	a  	 DT	O
period  	period  	 NN	O
of  	of  	 IN	O
at  	at  	 IN	O
least  	least  	 JJS	O
4  	4  	 CD	O
weeks  	weeks  	 NNS	O
in  	in  	 IN	O
addition  	addition  	 NN	O
to  	to  	 TO	O
the  	the  	 DT	O
standard  	standard  	 JJ	O
management  	management  	 NN	B-NP
plan 	plan 	 NN	I-NP
,  	,  	 ,	O
while  	while  	 IN	O
a  	a  	 DT	O
comparable  	comparable  	 JJ	O
group  	group  	 NN	O
of  	of  	 IN	O
subjects  	subjects  	 NNS	B-NP
( 	( 	 -LRB-	O
n  	n  	 CD	O
=  	=  	 SYM	O
39 	39 	 CD	O
)  	)  	 -RRB-	O
followed  	followed  	 VBD	O
the  	the  	 DT	O
standard  	standard  	 JJ	O
management  	management  	 NN	B-NP
plan  	plan  	 NN	I-NP
alone 	alone 	 RB	O
.  	.  	 .	O
All  	All  	 DT	O
subjects  	subjects  	 NNS	B-NP
( 	( 	 -LRB-	O
treatment  	treatment  	 NN	O
and  	and  	 CC	O
controls 	controls 	 NNS	O
)  	)  	 -RRB-	O
completed  	completed  	 VBD	O
the  	the  	 DT	O
follow-up  	follow-up  	 JJ	B-NP
period 	period 	 NN	I-NP
,  	,  	 ,	O
there  	there  	 EX	O
were  	were  	 VBD	O
no  	no  	 DT	O
dropouts  	dropouts  	 NNS	O
and  	and  	 CC	O
Meriva®  	Meriva®  	 NNP	B-NP
showed  	showed  	 VBD	O
an  	an  	 DT	O
optimal  	optimal  	 JJ	B-NP
tolerability 	tolerability 	 NN	I-NP
.  	.  	 .	O
At  	At  	 IN	O
4  	4  	 CD	O
weeks 	weeks 	 NNS	O
,  	,  	 ,	O
microcirculatory  	microcirculatory  	 NN	B-NP
and  	and  	 CC	O
clinical  	clinical  	 JJ	B-NP
evaluations  	evaluations  	 NNS	I-NP
indicated  	indicated  	 VBD	O
an  	an  	 DT	O
improvement  	improvement  	 NN	O
of  	of  	 IN	O
microangiopathy 	microangiopathy 	 NN	B-NP
.  	.  	 .	O
In  	In  	 IN	O
terms  	terms  	 NNS	O
of  	of  	 IN	O
peripheral  	peripheral  	 JJ	B-NP
microangiopathy 	microangiopathy 	 NN	I-NP
,  	,  	 ,	O
in  	in  	 IN	O
the  	the  	 DT	O
Meriva®  	Meriva®  	 JJ	O
group 	group 	 NN	O
,  	,  	 ,	O
there  	there  	 EX	O
was  	was  	 VBD	O
a  	a  	 DT	O
significant  	significant  	 JJ	O
improvement  	improvement  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
venoarteriolar  	venoarteriolar  	 JJ	B-NP
response  	response  	 NN	I-NP
( 	( 	 -LRB-	O
p  	p  	 CD	O
< 	< 	 SYM	O
0.05 	0.05 	 CD	O
)  	)  	 -RRB-	O
and  	and  	 CC	O
a  	a  	 DT	O
decrease  	decrease  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
score  	score  	 NN	O
of  	of  	 IN	O
peripheral  	peripheral  	 JJ	B-NP
oedema  	oedema  	 NNS	I-NP
( 	( 	 -LRB-	O
p  	p  	 CD	O
< 	< 	 SYM	O
0.05 	0.05 	 CD	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
a  	a  	 DT	O
sign  	sign  	 NN	O
typically  	typically  	 RB	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
the  	the  	 DT	O
failure  	failure  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
venoarteriolar  	venoarteriolar  	 JJ	B-NP
response 	response 	 NN	I-NP
.  	.  	 .	O
At  	At  	 IN	O
the  	the  	 DT	O
retinal  	retinal  	 JJ	B-NP
level 	level 	 NN	I-NP
,  	,  	 ,	O
high-resolution 	high-resolution 	 NNP	B-NP
,  	,  	 ,	O
duplex  	duplex  	 JJ	O
scanning 	scanning 	 NN	O
,  	,  	 ,	O
used  	used  	 VBN	O
to  	to  	 TO	O
measure  	measure  	 VB	O
retinal  	retinal  	 JJ	B-NP
flow 	flow 	 NN	I-NP
,  	,  	 ,	O
showed  	showed  	 VBD	B-NP
improvements  	improvements  	 NNS	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
Meriva®  	Meriva®  	 NN	B-NP
treated  	treated  	 VBN	O
patients 	patients 	 NNS	O
.  	.  	 .	O
The  	The  	 DT	O
evaluation  	evaluation  	 NN	O
of  	of  	 IN	O
retinal  	retinal  	 JJ	B-NP
oedema  	oedema  	 NNS	I-NP
( 	( 	 -LRB-	O
Steigerwalt 	Steigerwalt 	 NNP	O
's  	's  	 POS	O
scale 	scale 	 NN	O
)  	)  	 -RRB-	O
showed  	showed  	 VBD	O
an  	an  	 DT	O
improvement  	improvement  	 NN	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
improved  	improved  	 JJ	O
visual  	visual  	 JJ	O
acuity  	acuity  	 NNS	B-NP
( 	( 	 -LRB-	O
Snellen  	Snellen  	 NNP	B-NP
scale 	scale 	 NN	I-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
There  	There  	 EX	O
were  	were  	 VBD	O
no  	no  	 DT	O
clinical  	clinical  	 JJ	O
or  	or  	 CC	O
microcirculatory  	microcirculatory  	 JJ	B-NP
effects  	effects  	 NNS	I-NP
in  	in  	 IN	O
controls 	controls 	 NNS	O
.  	.  	 .	O
These  	These  	 DT	O
preliminary  	preliminary  	 JJ	B-NP
observations 	observations 	 NNS	I-NP
,  	,  	 ,	O
indicate  	indicate  	 VBP	O
the  	the  	 DT	O
value  	value  	 NN	O
of  	of  	 IN	O
curcumin 	curcumin 	 NN	B-NP
,  	,  	 ,	O
when  	when  	 WRB	O
administered  	administered  	 VBN	O
in  	in  	 IN	O
a  	a  	 DT	O
bioavailable  	bioavailable  	 JJ	B-NP
form  	form  	 NN	I-NP
as  	as  	 IN	O
with  	with  	 IN	O
Meriva® 	Meriva® 	 NNP	B-NP
,  	,  	 ,	O
in  	in  	 IN	O
the  	the  	 DT	O
management  	management  	 NN	O
of  	of  	 IN	O
diabetic  	diabetic  	 JJ	B-NP
microangiopathy  	microangiopathy  	 NN	I-NP
and  	and  	 CC	O
retinopathy 	retinopathy 	 NN	B-NP
.  	.  	 .	O
